Low Incidence Rates of Mucositis, Febrile Neutropenia or Sepsis in the Prospective, Randomized Phase 3 Sierra Trial for Patients with Relapsed or Refractory Acute Myeloid Leukemia with Targeted Delivery of Anti-CD45 Iodine (I-131) Apamistamab [Iomab-B]
JOURNAL OF NUCLEAR MEDICINE(2021)
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要